Houston-based Soliton, which has created a technology that uses sound to treat cellulite and scars, has been acquired. Photo via soliton.com

A California company has acquired Houston-based Soliton as well as its innovative device that uses sound to eliminate cellulite.

Allergan Aesthetics, an AbbVie company, has announced an agreement to acquire Soliton and its rapid acoustic pulse device RESONICTM, which recently received U.S. Food and Drug Administration clearance for the treatment of cellulite.

The company's team first developed the basis of the tool for tattoo removal and earned FDA clearance for that treatment a few years ago. Christopher Capelli and Walter Klemp co-founded Soliton in 2012.

The acquisition will take Soliton's technology to the next level, says Klemp, who serves as the company's executive chairman.

"Allergan Aesthetics' brand recognition, global footprint, track record and commitment to developing best-in-class aesthetic treatments makes the Company ideally suited to maximize the commercial potential of the RESONICTM rapid acoustic pulse technology," Klemp says in the release.

"I am proud of the passion and accomplishments of the Soliton team and thankful for the ongoing support of our investors which have culminated in this transaction," he continues. "We look forward to working with Allergan Aesthetics to ensure a successful completion of this transaction."

For Carrie Strom, president of Global Allergan Aesthetics and senior vice president at AbbVie, Soliton's solution has a great potential in the market. Soliton's clinical trial data that was submitted to the FDA showed that after a single treatment session, RESONICTM demonstrated significant improvement and strong patient satisfaction with 92.9 percent of subjects agreeing or strongly agreeing their cellulite appeared improved, per the release.

"There is a huge unmet need to address cellulite and effective treatments have been elusive and frustrating for consumers," Strom says in the release. "Soliton's technology offers a new, completely non-invasive approach with clinically-proven results to reduce the appearance of cellulite with no patient downtime.

"The addition of this technology complements Allergan Aesthetics' portfolio of body contouring treatments," she continues. "Health care providers will now have another option to address consumers' aesthetic concerns."

Brad Hauser, CEO of Soliton, previously told InnovationMap that the company's plans for 2021 included focusing on the commercialization of their product and get it into the hands of dermatologists, plastic surgeons, and other medical professionals for 25 key accounts — potentially including ones Houston — with a plan for a national rollout in 2022.

Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Read more about Garaizar and the TMC Venture Fund here.

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Read more about Klemp and Moleculin here.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Read more about Sutaria and ST&F here.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Read more about Jones and iCRYO here.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.

4 Houston-area schools excel with best online degree programs in U.S.

Top of the Class

Four Houston-area universities have earned well-deserved recognition in U.S. News & World Report's just-released rankings of the Best Online Programs for 2026.

The annual rankings offer insight into the best American universities for students seeking a flexible and affordable way to attain a higher education. In the 2026 edition, U.S. News analyzed nearly 1,850 online programs for bachelor's degrees and seven master's degree disciplines: MBA, business (non-MBA), criminal justice, education, engineering, information technology, and nursing.

Many of these local schools are also high achievers in U.S. News' separate rankings of the best grad schools.

Rice University tied with Texas A&M University in College Station for the No. 3 best online master's in information technology program in the U.S., and its online MBA program ranked No. 21 nationally.

The online master's in nursing program at The University of Texas Medical Branch in Galveston was the highest performing master's nursing degree in Texas, and it ranked No. 19 nationally.

Three different programs at The University of Houston were ranked among the top 100 nationwide:
  • No. 18 – Best online master's in education
  • No. 59 – Best online master's in business (non-MBA)
  • No. 89 – Best online bachelor's program
The University of Houston's Clear Lake campus ranked No. 65 nationally for its online master's in education program.

"Online education continues to be a vital path for professionals, parents, and service members seeking to advance their careers and broaden their knowledge with necessary flexibility," said U.S. News education managing editor LaMont Jones in a press release. "The 2026 Best Online Programs rankings are an essential tool for prospective students, providing rigorous, independent analysis to help them choose a high-quality program that aligns with their personal and professional goals."

A little farther outside Houston, two more universities – Sam Houston State University in Huntsville and Texas A&M University in College Station – stood out for their online degree programs.

Sam Houston State University

  • No. 5 – Best online master's in criminal justice
  • No. 30 – Best online master's in information technology
  • No. 36 – Best online master's in education
  • No. 77 – Best online bachelor's program
  • No. 96 – Best online master's in business (non-MBA)
Texas A&M University
  • No. 3 – Best online master's in information technology (tied with Rice)
  • No. 3 – Best online master's in business (non-MBA)
  • No. 8 – Best online master's in education
  • No. 9 – Best online master's in engineering
  • No. 11 – Best online bachelor's program
---

This article originally appeared on CultureMap.com.